Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Shenzhen Weiguang Biological Products Co., Ltd. (002880.SZ)
CNY21.49
+0.30 (+1.42%)
CN SHZ Healthcare Drug Manufacturers - Specialty & Generic
Address
No. 3402, Guangqiao Avenue 518107
Shenzhen, CN
Shenzhen, CN
CEO
Caiping Guo
Website
szwg.com
IPO
2017-06-16
ISIN CNE100002Q58
Description
Shenzhen Weiguang Biological Products Co., Ltd. is a Chinese enterprise primarily dedicated to the entire lifecycle of blood products, encompassing their research, development, manufacturing, and distribution within the domestic market. Its comprehensive portfolio features a range of crucial blood-derived therapies, including human albumin, various intravenous immunoglobulin preparations (such as pH4 and its freeze-dried counterpart), general human immunoglobulin, and specific immunoglobulins targeting conditions like hepatitis B, rabies, and tetanus. Additionally, it provides histamine human immunoglobulin and human fibrinogen. These offerings collectively represent nine distinct product types, available in twenty-one different specifications. Established in 1985, the firm maintains its headquarters in Shenzhen, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY21.49
+0.30 (+1.42%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
2M
Beta
0.31
Float Shares
56.45M
Free Float %
24.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.00% | -3.92% | -2.02% | -16.88% | -4.69% | -1.10% | -11.54% | -24.78% | -31.97% | +46.46% | +46.46% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
21.49
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
4.30
Safe zone
Piotroski F-Score
4 / 9
Average
MOAT Score
5 / 10
Developing
Composite Rating
B
Overall Score
3 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
2 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+5.3% Q1'26: -1.4% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%-2.7% Q1'26: -26.3% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+3.8% ★ Q1'26: -64.2% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+24.0% ★ Q1'26: +19.6% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+9.2% ★ Q1'26: +4.3% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+0.0% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×1.73× Q1'26: 4.40× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
623.39M
est: 374.80M (+66.3%)
|
687.95M
est: 779.30M (-11.7%)
|
821.47M
est: 978.00M (-16.0%)
|
904.56M
est: 913.00M (-0.9%)
|
1.14B
est.
|
907.43M
est: 1.39B (-34.5%)
|
1.05B
est: 1.06B (-1.0%)
|
667.93M
est: 1.06B (-36.9%)
|
1.20B
est: 1.18B (+1.6%)
|
1.27B
est: 1.11B (+14.0%)
|
1.30B
1.30B – 1.30B
+16.7% YoY
|
1.40B
1.40B – 1.40B
+7.6% YoY
|
1.50B
1.50B – 1.50B
+7.3% YoY
|
| EBITDA |
232.47M
est: 122.51M (+89.8%)
|
227.55M
est: 254.74M (-10.7%)
|
238.64M
est: 319.69M (-25.4%)
|
265.95M
est: 298.44M (-10.9%)
|
373.30M
est.
|
298.68M
est: 453.06M (-34.1%)
|
347.03M
est: 346.17M (+0.3%)
|
203.58M
est: 346.17M (-41.2%)
|
435.27M
est: 399.96M (+8.8%)
|
458.41M
est: 375.21M (+22.2%)
|
437.87M
437.87M – 437.87M
+16.7% YoY
|
471.36M
471.36M – 471.36M
+7.6% YoY
|
505.78M
505.78M – 505.78M
+7.3% YoY
|
| EBIT |
190.88M
est: 92.67M (+106.0%)
|
185.73M
est: 192.69M (-3.6%)
|
198.85M
est: 241.82M (-17.8%)
|
220.23M
est: 225.74M (-2.4%)
|
282.37M
est.
|
244.23M
est: 342.70M (-28.7%)
|
260.77M
est: 261.84M (-0.4%)
|
139.37M
est: 261.84M (-46.8%)
|
319.60M
est: 291.83M (+9.5%)
|
303.91M
est: 273.77M (+11.0%)
|
319.49M
319.49M – 319.49M
+16.7% YoY
|
343.93M
343.93M – 343.93M
+7.6% YoY
|
369.05M
369.05M – 369.05M
+7.3% YoY
|
| Net Income |
154.75M
est: 191.16M (-19.0%)
|
156.64M
est: 228.96M (-31.6%)
|
171.34M
est: 307.80M (-44.3%)
|
190.40M
est: 208.98M (-8.9%)
|
254.34M
est.
|
205.44M
est: 302.94M (-32.2%)
|
218.65M
est: 235.87M (-7.3%)
|
117.52M
est: 235.87M (-50.2%)
|
253.52M
est: 251.74M (+0.7%)
|
246.32M
est: 222.26M (+10.8%)
|
207.52M
207.52M – 207.52M
-6.6% YoY
|
237.00M
237.00M – 237.00M
+14.2% YoY
|
273.29M
273.29M – 273.29M
+15.3% YoY
|
| SGA |
59.80M
est: 23.40M (+155.6%)
|
69.10M
est: 48.65M (+42.0%)
|
77.13M
est: 61.05M (+26.3%)
|
81.60M
est: 56.99M (+43.2%)
|
71.29M
est.
|
88.45M
est: 86.52M (+2.2%)
|
126.94M
est: 66.11M (+92.0%)
|
91.67M
est: 66.11M (+38.7%)
|
121.81M
est: 115.84M (+5.2%)
|
40.57M
est: 108.67M (-62.7%)
|
126.82M
126.82M – 126.82M
+16.7% YoY
|
136.52M
136.52M – 136.52M
+7.6% YoY
|
146.49M
146.49M – 146.49M
+7.3% YoY
|
| EPS |
0.78
est: 0.84 (-7.5%)
|
0.69
est: 1.01 (-31.7%)
|
0.76
est: 1.36 (-44.0%)
|
0.84
est: 0.92 (-8.8%)
|
1.12
est.
|
0.91
est: 1.34 (-31.9%)
|
0.96
est: 1.04 (-7.7%)
|
0.52
est: 1.04 (-50.0%)
|
1.12
est: 1.11 (+0.9%)
|
1.09
est: 0.98 (+11.2%)
|
0.92
0.92 – 0.92
-6.6% YoY
|
1.05
1.05 – 1.05
+14.2% YoY
|
1.21
1.21 – 1.21
+15.3% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-28 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-27 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-26 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-25 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-22 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-21 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-20 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-19 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-18 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-15 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-14 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-13 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-12 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-11 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-08 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-07 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-05-06 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-30 | B | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-29 | B | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-28 | B | 3/5 | 1/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-27 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-24 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-23 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-22 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-21 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-20 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-17 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-16 | B- | 3/5 | 1/5 | 3/5 | 5/5 | 1/5 | 2/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
65.89M
OE per share TTM
0.29
Owner's Yield
1.15%
Maintenance CapEx ratio
87.66%
Maint CapEx / Avg PPE
70.9%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 4 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.01% | 74.2K | 0.65% |
| 2 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 81.2K | 0.39% |
| 3 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 45.6K | 0.29% |
| 4 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 31.7K | 0.28% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
353.8K
Shares Outstanding
226.80M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Caiping Guo | GM & Director | — | female |
| Guan Qun Chen | CFO & Director | — | male |
| Jianjun Jin | Secretary & Marketing Director | — | male |
| Kui Huang | Accounting Supervisor | — | — |
| Wenjie Xie | Deputy GM & Director | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 002880.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
